Improving adherence - Money isn't the only thing

New England Journal of Medicine

Volumn 365, Issue 22, 2011, Pages 2131-2133

  Goldman, Lee ^a   Epstein, Arnold M ^b  

^a Department of Medicine   (United States)

^b HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; GENERIC DRUG; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR;

ACUTE HEART INFARCTION; ADVERSE OUTCOME; CARDIOVASCULAR RISK; DRUG COST; DRUG INDUSTRY; EDITORIAL; HAZARD RATIO; HEALTH CARE COST; HEALTH SERVICE; HUMAN; INSURANCE; PATIENT COMPLIANCE; PRIORITY JOURNAL; REVASCULARIZATION; RISK REDUCTION;

EID: 82555192210     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMe1111558     Document Type: Editorial

References (11)

1. Choudhry NK, Patrick AR, Antman EM, Avorn J, Shrank WH. Cost-effectiveness of providing full drug coverage to increase medication adherence in post-myocardial infarction Medicare beneficiaries. Circulation 2008;117:1261-8. (Pubitemid 351365674)
2. Department of Health and Human Services. Hospital Compare: hospital process of care measures tables (http://www.hospital compare.hhs.gov/ staticpages/for-consumers/poc/explainations-of-measures.aspx).
3. Fonarow GC, French WJ, Frederick PD. Trends in the use of lipid-lowering medications at discharge in patients with acute myocardial infarction: 1998 to 2006. Am Heart J 2009;157:185-94.
4. Fendrick AM, Smith DG, Chernew ME, Shah SN. A benefit-based copay for prescription drugs: patient contribution based on total benefits, not drug acquisition cost. Am J Manag Care 2001;7:861-7. (Pubitemid 32904146)
5. Choudhry NK, Avorn J, Glynn RJ, et al. Full coverage for preventive medications after myocardial infarction. N Engl J Med 2011;365:2088-97.
6. Hunink MG, Goldman L, Tosteson AN, et al. The recent decline in mortality from coronary heart disease, 1980-1990: the effect of secular trends in risk factors and treatment. JAMA 1997;277:535-42. (Pubitemid 27083982)
7. Osterberg L, Blaschke T. Adherence to medication. N Engl J Med 2005;353:487-97.
8. Austvoll-Dahlgren A, Aaserud M, Vist G, et al. Pharmaceutical policies: effects of cap and co-payment on rational drug use. Cochrane Database Syst Rev 2008;1:CD007017.
9. Gibson TB, Wang S, Kelly E, et al. A value-based insurance design program at a large company boosted medication adherence for employees with chronic illnesses. Health Aff (Millwood) 2011;30:109-17.
10. Choudhry NK, Rosenthal MR, Milstein A. Assessing the evidence for value-based insurance design. Health Aff (Millwood) 2010;29:1988-94.
11. Lazar LD, Pletcher MJ, Coxson PG, Bibbins-Domingo K, Goldman L. Cost-effectiveness of statin therapy for primary prevention in a low-cost statin era. Circulation 2011;124:146-53.